Supporting A Rapidly Growing Biotech With A Unique Ocular Gene Therapy

An emerging biotech company developing a viral vector-based gene therapy needed a flexible and experienced partner to navigate the complex transition from preclinical studies to first-in-human trials. Supporting the evolving needs of this rapidly advancing program required a coordinated, multidisciplinary approach across multiple critical areas, including drug metabolism, toxicology, bioanalysis, CMC testing, central laboratory services, and early clinical development.

By streamlining efforts and ensuring seamless integration across these functions, we provided the expertise and infrastructure necessary to accelerate the biotech's path to the clinic while maintaining scientific rigor and regulatory compliance.